Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visnadine is a natural vasodilator classified as an angular pyranocoumarin, first isolated from the plant Ammi visnaga (bishop's weed), which has been used in traditional Egyptian medicine for its spasmolytic and cardiovascular effects[1][2][3]. It acts primarily by inhibiting contractile responses mediated by calcium entry through L-type calcium channel, resulting in relaxation of smooth muscle and widening of blood vessels[3][6]. This mechanism improves circulation, including microcirculation in small blood vessels[5]. Visnadine has been investigated for use in treating angina pectoris, peripheral vasculopathies, and as a topical agent to enhance regional vascularization. A notable application is the ReFeel spray (IDI Integratori Dietetici Italiani), developed for vulvar use to improve sexual function and local vascular response in women with or without female sexual dysfunction; clinical studies have shown it to be well tolerated with positive effects on sexual function[3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on visnadine.